The Dutch Pregnancy Drug Register: Suitable to Study Paternal Drug Exposures?

Annerose E. van der Mijle (), Petra J. Woestenberg, Leanne J. Kosse and Eugène P. van Puijenbroek
Additional contact information
Annerose E. van der Mijle: Netherlands Pharmacovigilance Centre Lareb, 5237 MH Hertogenbosch, The Netherlands
Petra J. Woestenberg: Netherlands Pharmacovigilance Centre Lareb, 5237 MH Hertogenbosch, The Netherlands
Leanne J. Kosse: Netherlands Pharmacovigilance Centre Lareb, 5237 MH Hertogenbosch, The Netherlands
Eugène P. van Puijenbroek: Netherlands Pharmacovigilance Centre Lareb, 5237 MH Hertogenbosch, The Netherlands

IJERPH, 2023, vol. 20, issue 23, 1-9

Abstract: Paternal medication use around the time of conception is common, but information about its effects on pregnancy outcome and the health of the child is generally limited. The aim of this study is to examine the feasibility of studying paternal exposure in the Dutch Pregnancy Drug Register by using immunosuppressants as a proof of concept. In 113 of 15,959 pregnancies, long-term paternal immunosuppressant use was reported 3 months before conception. In total, 134 immunosuppressants were used. Pregnancy outcome was known for 54 cases and was in accordance with previous findings. Two spontaneous abortions, two premature births, six small for gestational age babies, and two major congenital malformations were reported. Time to pregnancy (TTP) was known for 9548 pregnancies, including 89 with paternal immunosuppressant use. TTP analysis did not show a difference in pregnancies with paternal immunosuppressant use compared to the control group. Moreover, the number of fertility treatments in the paternal immunosuppressant group was similar to the control group. In our opinion, it is feasible to use the Dutch Pregnancy Drug Register to study the effects of paternal exposure on pregnancy outcome. However, to study the potential effects on fertility, more information is needed, particularly since the beginning of pregnancy attempts.

Keywords: paternal exposure; Dutch Pregnancy Register; pregnancy outcome; immunosuppressants; pregnancy; medication; infant health; birth defect; fertility; time to pregnancy (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/23/7107/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/23/7107/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2023:i:23:p:7107-:d:1286731

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().